Objective-Vascular calcification is highly correlated with increased cardiovascular morbidity and mortality. C1q/tumor necrosis factor-related protein-3 (CTRP3) is a newly identified adipokine that plays important roles in cardiovascular system. Here, we investigated the role of CTRP3 in vascular calcification and its underlying mechanism. Approach and Results-Adenine-induced chronic renal failure rat model was used to mimic the process of arterial medial calcification. The level of CTRP3 was elevated in serum and abdominal aorta of chronic renal failure rats. Periadventitial gene delivery of CTRP3 significantly accelerated the calcification of abdominal aorta and arterial ring. In cultured vascular smooth muscle cells (VSMCs), CTRP3 increased β-glycerophosphate-induced calcium deposition and alkaline phosphatase activity. Although CTRP3 alone was not sufficient to induce calcification in VSMCs, it upregulated the expression of osteogenic marker genes including runt-related transcription factor 2 (Runx2), bone morphogenetic protein 2, and osteopontin. CTRP3 further enhanced β-glycerophosphate-induced downregulation of smooth muscle α-actin and smooth muscle 22α, while augmenting osteogenic marker expression in VSMCs induced by β-glycerophosphate. In contrast, knockdown of CTRP3 in VSMCs potently suppressed β-glycerophosphate-induced calcification. Mechanistically, knockdown of Runx2 inhibited CTRP3-promoted VSMC calcification. CTRP3 increased extracellular signal-regulated kinase 1/2 phosphorylation and reactive oxygen species production. Preincubation with U0126, an extracellular signalregulated kinase 1/2 upstream kinase inhibitor, had no effect on CTRP3-induced reactive oxygen species production. However, pretreatment with N-acetyl-l-cysteine, a reactive oxygen species scavenger, suppressed CTRP3-induced extracellular signal-regulated kinase 1/2 phosphorylation. Both N-acetyl-l-cysteine and U0126 significantly inhibited CTRP3-induced upregulation of Runx2 and calcified nodule formation. 
V ascular calcification is a chronic condition and is associated with high morbidity and mortality of cardiovascular diseases. 1 An imbalance between inducers and inhibitors has been suggested to play a critical role in the pathological process of vascular calcification. 2 Adipokines, predominantly secreted by adipose tissue, are a series of factors controlling energy metabolism, inflammation, and cardiovascular function. 3 Accumulating evidence has suggested that adipokines are involved in the regulation of vascular calcification. Leptin enhances the osteoblastic differentiation and calcification in cultured cells as well as apolipoprotein E-deficient mice. 4, 5 In contrast, several adipokines, including adiponectin, omentin, and apelin, can play a protective role against vascular calcification by inhibiting osteoblastic differentiation of vascular smooth muscle cells (VSMCs). [6] [7] [8] However, the precise roles of adipokines in vascular calcification regulation and the underlying mechanisms still require further investigation.
C1q/tumor necrosis factor-related protein-3 (CTRP3) is a newly identified adipokine with important roles in regulation of inflammation and metabolism. 9 CTRP3 is ubiquitously expressed in adipose, kidney, cartilage, fibroblasts, chondrocytes, monocytes, and VSMCs. [10] [11] [12] CTRP3 reduces glucose output in hepatocytes and exerts anti-inflammatory effect in adipocytes and monocytes. 13, 14 A recent study shows that CTRP3 also has antiapoptotic, proangiogenic, and cardioprotective roles.
Because CTRP3 promotes proliferation of endothelial cells, VSMCs, chondrogenic precursors, and chondrocytes, 12, 16, 17 we hypothesized that CTRP3 might be involved in the regulation of vascular calcification. In this study, we investigated the effects of CTRP3 on vascular calcification in chronic renal failure (CRF) rat, arterial ring, and primary cultured VSMCs. We also explored the underlying mechanism of CTRP3-mediated osteogenic transition and calcification of VSMCs.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Changes in Blood Biochemical Parameters
Rat CRF was induced by adenine diet to mimic the process of arterial medial calcification. The adenine-fed rats had severe renal failure, with a significant increase in blood urea nitrogen and creatinine at 4 weeks (P<0.01) and even higher at 6 weeks (P<0.01), similar to a previous report. 18 Serum calcium level of CRF rats did not change, whereas serum phosphorus increased by 41.4% at 4 weeks and 79.6% at 6 weeks (P<0.01) compared with the age-matched controls. Body weight and abdominal fat weight were decreased in CRF rats (Table in the online-only Data Supplement). In addition, blood biochemical parameters were not affected by periadventitial delivery of recombinant adenovirus carrying full-length CTRP3 (Ad-CTRP3) or green fluorescent protein (Ad-GFP) to abdominal aortas, compared with the age-matched CRF rats.
Increased CTRP3 Is Associated With Vascular Calcification in CRF Rats
ELISA showed that the level of circulating CTRP3 increased to 783±48 ng/mL in 4-week and 791±41 ng/mL in 6-week CRF rats compared with 667±35 ng/mL in control ( Figure 1A ). The expression of CTRP3 mRNA in kidney and abdominal adipose tissue decreased significantly in CRF rats, whereas adenoviral delivery of CTRP3 or GFP did not change the local CTRP3 mRNA levels ( Figure 1B and 1C) . The amplified CTRP3 sequence after reverse transcriptionpolymerase chain reaction was detected at the size of 272 bp, and CTRP3 protein was observed with a molecular mass of ≈ 36 kDa in VSMCs ( Figure 1D ). Adipose tissue obtained from control rats was used as a positive control. CTRP3 proteins increased in the abdominal aortas of 4-week (P<0.05) and further increased in 6-week CRF rats (P<0.01) compared with controls ( Figure 1E ). Histological assessment with alizarin red staining showed extensive linear calcification in the aortic media of 6-week CRF rats. Immunohistochemical staining showed that CTRP3 expression was slightly increased in the aortic media in 4-week, whereas abundantly accumulated in 6-week CRF rats. Moreover, the CTRP3-positive cells were mainly localized to the calcified area, which was defined as the area stained reddish/purple by alizarin red staining ( Figure I in the online-only Data Supplement). These results suggested that increased CTRP3 expression might be involved in aortic medial calcification of CRF rats.
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Overexpression of CTRP3 Promotes Vascular Calcification in CRF Rats and in High-Phosphate Cultured Carotid Arterial Rings
To further explore the role of CTRP3 in vascular calcification, we periadventitially delivered Ad-CTRP3 or Ad-GFP to rat abdominal aortas. Calcification of abdominal aortas was induced by adenine diet after 6 weeks, as demonstrated by alizarin red staining and calcium deposition (Figure 2A and 2B). Ad-GFP transfection did not change calcium deposition in the abdominal aortas as compared with CRF rats. In contrast, Ad-CTRP3 markedly increased calcium deposition and calcified nodule formation. Quantitative fluorescence analysis showed that the expression of Ad-CTRP3 in CRF rat transfected aortas was markedly increased at 1 week and returned to control level after 6 weeks ( Figure 2C ). We further evaluated the effect of CTRP3 on vascular calcification in a rat carotid ring organ culture model. Rat common carotid arteries were removed 3 days after Ad-GFP or Ad-CTRP3 transfection, cut into 2-to 3-mm rings, and were cultured in regular DMEM with or without high phosphate (3.8 mmol/L PO 4 3− ) for 6 days. Ad-CTRP3-transfected carotid explants showed much more calcification than Ad-GFPtransfected explants in high-phosphate medium ( Figure 2D and 2E). Although overexpression of CTRP3 increased alkaline phosphatase (ALP) protein expression, it was not sufficient to induce calcium deposition calcified nodule formation ( Figure 2F -2H) when carotid explants were cultured without high phosphate. Thus, these results indicated that overexpression of CTRP3 enhanced vascular calcification in CRF rats and in high-phosphate cultured carotid arterial rings.
CTRP3 Promotes β-Glycerophosphate-Induced
VSMC Calcification In Vitro
We further examined the in vitro effects of CTRP3 on arterial calcification in cultured primary VSMCs induced by β-glycerophosphate (βGP). Compared with VSMCs treated with βGP alone, calcium concentration was significantly increased in the presence of various concentrations of CTRP3 (1, 2, and 4 μg/mL) as early as day 3 and further increased at day 6 and 12 ( Figure 3A ). Similarly, ALP activity was also elevated in the presence of various concentrations of CTRP3 ( Figure 3B ). However, CTRP3 alone did not increase calcium concentration and calcified nodule formation when VSMCs were cultured without βGP, consistent with in vivo finding that CTRP3 was not sufficient to induce calcification. The intensity of alizarin red staining was significantly higher in βGP+CTRP3 (2 μg/mL) group compared with βGP group. Knockdown of CTRP3 expression by small interfering RNA reduced βGP-induced calcified nodule formation, compared with scramble small interfering RNA control ( Figure 3C-3F ). The data indicated that CTRP3 promoted βGP-induced VSMCs calcification in vitro.
CTRP3 Promotes Phosphate-Induced Osteogenic Transition of VSMCs
VSMC phenotypic transition from contractile to osteogenic phenotype plays a crucial role in vascular calcification. 19 We evaluated the effect of CTRP3 on VSMC transition both in vivo and in vitro. As shown in Figure 4A and 4B, the expression of contractile markers smooth muscle α-actin (SMA) and smooth muscle 22α in the abdominal aorta of 6-week CRF rats was significantly decreased by 31.9% and 27.3%, respectively, compared with the control group (P<0.01). On Ad-CTRP3 transfection, the contractile marker expression further decreased by 53.9% and 52.7% (P<0.01) compared with CRF rats. Ad-GFP transfection did not alter the expression of contractile marker genes. On the contrary, the osteogenic markers runt-related transcription factor 2 (Runx2) and bone morphogenetic protein 2 were significantly increased in CRF rats (P<0.01) and were further elevated in Ad-CTRP3-transfected group (P<0.01; Figure 4C and 4D). The observation was also verified by immunohistochemical staining of SMA and Runx2 ( Figure II in the online-only Data Supplement).
Similarly, the expression of SMA and smooth muscle 22α at both mRNA and protein levels was decreased in VSMCs treated with βGP+CTRP3 (2 μg/mL) for 48 hours ( Figure 5A-5D ). In parallel, the levels of Runx2, bone morphogenetic protein 2, and osteopontin mRNA ( Figure 5A and 5B) and protein (Figure 5E-5G) were markedly increased in βGP+CTRP3-treated VSMCs. CTRP3 alone upregulated the expression of Runx2, bone morphogenetic protein 2, osteopontin, sex-determining region Y-box 9, and collagen type II α1. However, it did not affect SMA level and even increased smooth muscle 22α level slightly, when VSMCs were incubated without βGP for 48 hours ( Figure 5H-5N) . These results indicated that CTRP3 promoted phosphateinduced osteogenic transition of VSMCs both in vivo and in vitro.
Knockdown of Runx2 Inhibits CTRP3-Promoted VSMC Calcification In Vitro
Among various inducers of vascular calcification, Runx2 is an important transcription factor to accelerate osteogenic transition of VSMCs. 20 CTRP3 increased the expression of Runx2 in the abdominal aortas of CRF rats and in cultured VSMCs as described above. To explore whether Runx2 mediates the VSMC calcification promoted by CTRP3, VSMCs were transfected with small interfering RNA against Runx2 for 48 hours and then were incubated with 2 μg/mL CTRP3 in the presence of βGP for 12 days. Although CTRP3 significantly enhanced calcified nodule formation in the presence of βGP, Runx2 depletion dramatically abrogated this enhancement by CTRP3 ( Figure 5O and 5P) . These results suggested that Runx2 was essential for CTRP3-promoted VSMC calcification.
CTRP3 Upregulates Runx2 Expression and Promotes VSMC Calcification Through a Reactive Oxygen Species-Extracellular Signal-Regulated Kinase 1/2-Dependent Pathway
Mitogen-activated protein kinase (MAPK) pathway has been reported to play an important role in the proliferation of mesenchymal chondroprogenitor cells stimulated by CTRP3. 21 To reveal the intracellular signaling molecules mediating the effect of CTRP3, we measured phosphorylation of MAPK family in VSMCs. The levels of phospho-extracellular signalregulated kinase 1/2 (p-ERK1/2) were significantly increased after incubation with 2 μg/mL CTRP3 for 5, 15, and 30 minutes ( Figure 6A and 6B) . On the contrary, the levels of phosphop38MAPK and phospho-c-Jun N-terminal kinase were not changed within 60 minutes of CTRP3 treatment ( Figure 6A ).
Hydrogen peroxide is found to promote osteogenic transition of VSMCs, suggesting that reactive oxygen species (ROS) production may be involved in vascular calcification.
22 CTRP3 (2 μg/mL) increased the production of ROS in VSMCs ( Figure 6C) . Angiotensin II (100 nmol/L) was used as a positive control. 23 To examine whether the increased ROS was attributable to ERK1/2 signaling activation, we pretreated VSMCs with U0126 (10 nmol/L), an ERK1/2 upstream kinase inhibitor. Interestingly, blocking ERK1/2 signaling had no effect on CTRP3-induced ROS production ( Figure 6C ). On the contrary, pretreatment with N-acetyl-l-cysteine (20 μmol/L), a potent ROS scavenger, significantly suppressed CTRP3-induced ERK1/2 phosphorylation (P<0.01; Figure 6D ), suggesting that ROS production in turn activated ERK1/2 pathway. Induction of Runx2 by CTRP3 was significantly inhibited by N-acetyl-l-cysteine (20 μmol/L), PD98059 (an ERK1/2 upstream kinase inhibitor; 20 nmol/L), or U0126 (10 nmol/L) pretreatment in the present of βGP ( Figure 6E ). In addition, CTRP3-enhanced calcified nodule formation in the presence of βGP was suppressed by ROS scavenger or ERK1/2 kinase inhibitors ( Figure 6F and 6G) . Even in the absence of βGP, the induction of Runx2 expression by CTRP3 could be inhibited by N-acetyl-l-cysteine (20 μmol/L), PD98059 (20 nmol/L), or U0126 (10 nmol/L) pretreatment ( Figure 6H and 6I) . These results indicated that CTRP3 promoted ROS production, which in turn activated ERK1/2-Runx2 signaling pathway to enhance phosphate-induced osteogenic transition of VSMCs.
Discussion
There are 3 major new findings presented by our study. First, we demonstrated for the first time that CTRP3 promoted phosphateinduced vascular calcification in vivo, ex vivo, and in vitro. Second, we revealed that CTRP3 accelerated βGP-induced osteogenic transition of VSMCs by downregulating contractile markers and upregulating osteogenic markers. Third, although Runx2 was an essential mediator of CTRP3 response, increased ROS production and ERK1/2 activation also facilitate the CTRP3-induced Runx2 upregulation and VSMC calcification. Our results provide new insights into the important roles of CTRP3 in cardiovascular system and characterize a novel mechanism of adipokine-modulated vascular calcification.
CTRP3 is ubiquitously expressed in adipose and nonadipose tissues, and circulating levels of CTRP3 vary according to mammalian species and determining methods. Plasma CTRP3 concentration is ≈1000±300 ng/mL in mice by immunoblot analysis. 13 A recent report indicates that plasma CTRP3 levels in normal subjects are 226.2 to 335.5 ng/mL. 24 In addition, circulating CTRP3 levels is affected by food intake and disease types. Circulating CTRP3 in fasted mice increases compared with fasted/refed or ad libitum fed mice. Although CTRP3 is reduced in diet-induced obese mice with high leptin levels, it is increased in leptin-deficient obese mice. 13 In patients with glucose metabolism disorder, plasma CTRP3 level elevates significantly. 24 A 3-month combined exercise decreases CTRP3 level from 444.3 to 374.4 ng/ mL in obese Korean women. 25 These results suggest that circulating CTRP3 level may serve as a novel biomarker candidate for metabolic-related diseases. Vascular calcification is a critical event in the development of vascular disease and frequently observed in patients with CRF. 26 However, circulating levels of CTRP3 in patients with CRF or CRF animals are unknown. Here, with a CTRP3-specific ELISA kit, we showed that serum CTRP3 concentration in control rats was 667±35 ng/mL. Although CTRP3 levels in serum and calcified vasculature increased in CRF rats, the expression of CTRP3 mRNA decreased in kidney and abdominal adipose tissue. Because VSMC is not the main source of CTRP3, 11 one possible explanation for elevated serum CTRP3 was attributable to decreased renal function characterized by increased blood urea nitrogen and creatinine, which was in accordance with the finding by Choi et al. 24 Moreover, elevation A and B, VSMCs were incubated with 2 μg/mL CTRP3 and 10 mmol/L βGP for 3 days and then mRNA expression of contractile and osteogenic marker genes were determined by reverse transcription-polymerase chain reaction and normalized to that of β-actin. *P<0.05 vs βGP (n=3-5). C to G, VSMCs were incubated with 2 μg/mL CTRP3 and βGP for 6 to 48 hours, and the protein expression of smooth muscle α-actin (SMA; C), smooth muscle 22α (SM22α; D), Runx2 (E), bone morphogenetic protein 2 (BMP2; F), and osteopontin (OPN; G) was examined by Western blot and normalized to that of actin. *P<0.05 vs untreated. #P<0.05 vs βGP alone (n=5). H to N, VSMCs were incubated in the presence or absence of 2 μg/mL CTRP3 or 10 mmol/L βGP for 48 hours, and the protein expression of SMA (H), SM22α (I), Runx2 (J), BMP2 (K), osteopontin (L), sex-determining region Y-box 9 (Sox 9; M) and collagen type II α1 (COL2A1; N) was examined by Western blot and normalized to that of actin. *P<0.05, **P<0.01 vs untreated. #P<0.05 vs βGP (n=3). O and P, VSMCs were transfected with scramble small interfering RNA (siRNA) or Runx2 siRNA for 48 hours and then incubated with 2 μg/mL CTRP3 in the presence of 10 mmol/L βGP for an additional 12 days. O, VSMCs were stained for mineralization with alizarin red. Bar=100 μm. P, Quantitative analysis of calcified nodule formation. *P<0.05 vs βGP. #P<0.05 vs βGP+CTRP3 (n=5).
of CTRP3 in serum and vasculature appeared before calcified nodule formation, implying that CTRP3 might be involved in the development of vascular calcification. CTRP3 is a multifunctional adipokine in regulating cell metabolism and function, and its biological effect may vary depending on cell type, physiological, and pathological stimuli. By using periadventitial adenoviral delivery of CTRP3 both in vivo and ex vivo, we showed increased vascular calcification in CTRP3-overexpressed CRF rats. Our results in cultured VSMCs further confirmed the effects of CTRP3 on phosphate-induced vascular calcification. Knockdown of CTRP3 in VSMCs eliminated βGP-induced calcified nodule formation. We also noticed that, without βGP, CTRP3 alone was not sufficient to induce calcification in VSMCs. These results suggested that high phosphate was an independent risk of vascular calcification, and CTRP3 acted synergistically with phosphate to promote the progression of VSMC calcification.
Vascular calcification is an active and cell-mediated process. 19, 27 Many studies have revealed that phenotypic transition of VSMCs from contractile to osteogenic phenotype contributes to adipokine-participated vascular calcification. Treatment of calcifying VSMCs with leptin causes a significant increase in ALP activity, an early marker of osteogenic transition of VSMCs. 4 Adiponectin inhibits ALP activity, osteocalcin secretion, and Runx2 expression of calcifying VSMCs. 6 Omentin and apelin inhibit ALP activity and osteocalcin production during the osteoblastic differentiation of calcifying VSMCs. 7, 8 In the present study, we found that expressions of SMA and smooth muscle 22α were significantly decreased in the abdominal aortas of CRF rats, and overexpression of CTRP3 further reduced the expression of contractile markers. In contrast, increased osteogenic markers in CRF rats were further upregulated in CTRP3-overexpressed vasculature. In cultured VSMCs, CTRP3 alone increased the expression of osteogenic markers, but did not decrease the expression of contractile markers. Moreover, CTRP3 promoted βGP-induced osteogenic transition. These results further indicated that CTRP3 acted as a promoter instead of an inducer of VSMCs calcification.
Several key transcription factors such as Runx2, osterix, and Msx2 have been identified in calcified vascular lesions. 27 Among them, Runx2 is thought to be a decisive factor and early marker of VSMC osteogenic transition and calcification. 27, 28 Compared with the trace expression in normal vasculature, Runx2 is significantly upregulated in the vascular lesions and seems to precede overt calcification. 27 More importantly, Runx2 is closely associated with the effects of various adipokines in osteogenic transition of VSMCs. Adiponectin and apelin decrease Runx2 expression in cultured calcifying VSMCs, 6, 8 whereas tumor necrosis factor-α enhances the mRNA expression and DNA binding of Runx2. 29, 30 Here, we found that the expression of Runx2 increased significantly in the abdominal aortas of CRF rats. Overexpression of CTRP3 or treatment of VSMCs with CTRP3 further upregulated Runx2 expression. Knockdown of Runx2 reversed the effect of CTRP3 on VSMC calcification in vitro. These results suggested that Runx2 played a crucial role in CTRP3-promoted vascular calcification.
To gain further insight into the mechanisms by which CTRP3 promoted vascular calcification, we explored the intracellular signaling events in VSMCs. MAPK family activation plays a critical role in mediating the effects of adipokines on vascular calcification. However, the specific roles of major members of MAPK family, including ERK1/2, c-Jun N-terminal kinase, and p38MAPK, in vascular calcification depend on the stimuli and cell types. Adiponectin exerts its anticalcific effect through p38MAPK, 6 whereas apelin plays a protective role against vascular calcification via ERK1/2 pathway. 8 CTRP3 is reported to promote mouse VSMC proliferation via ERK1/2 and p38MAPK, 12 and it also promotes the proliferation and migration of murine osteosarcoma cells and endothelial cells by activating ERK1/2.
16,31 Here, we found that CTRP3 increased phosphorylation of ERK1/2 but not c-Jun N-terminal kinase and p38MAPK in VSMCs, suggesting that ERK1/2 was required in CTRP3-promoted vascular calcification.
Oxidative stress plays an important role in the pathogenesis of vascular calcification. 2 As a classical oxidative stressor and key mediator of intracellular signaling, hydrogen peroxide promotes osteogenic transition of VSMCs by upregulating Runx2. 22 We found that CTRP3 significantly increased intracellular ROS production. N-acetyl-l-cysteine pretreatment inhibited CTRP3-induced Runx2 upregulation and calcified nodule formation, which suggested that ROS production was involved in CTRP3-mediated Runx2 upregulation and VSMC calcification. Many studies revealed ERK1/2 as a downstream effector of ROS, whereas a report by Lu and Cederbaum 32 suggests a reciprocal relationship between ROS production and ERK activation. Here, we showed that ROS scavenger pretreatment significantly suppressed CTRP3-induced ERK1/2 phosphorylation, whereas inhibition of ERK1/2 did not affect CTRP3-induced ROS production, suggesting that ROS acted as an upstream molecule of ERK1/2 in CTRP3-treated VSMCs. Both ERK1/2 inhibitor and ROS scavenger reversed CTRP3-induced Runx2 upregulation and calcified nodule formation. Hence, CTRP3 promoted osteogenic transition and calcification of VSMCs through ROS-ERK1/2 signaling pathway. Although adenine-induced CRF model is demonstrated to be a useful model for the study of vascular calcification, adenine diet causes weight loss and faster development of vascular calcification than that in humans. 33, 34 Whether the extensive medial calcification is attributable to weight loss or the adenine itself remains to be determined. 33 More importantly, the effect of CTRP3 on vascular calcification in patients with CRF needs further investigation.
In summary, we have demonstrated that CTRP3 is a novel endogenous regulator of vascular calcification. CTRP3 promotes vascular calcification by accelerating phosphate-induced osteogenic transition of VSMCs through ROS-ERK1/2-Runx2 signaling pathway. These findings provide novel insight on the physiological and pathophysiological roles of CTRP3.
Vascular calcification is a chronic condition and is associated with high morbidity and mortality of cardiovascular disease. Among various regulators of vascular calcification, adipokines have drawn more attention in recent years. C1q/tumor necrosis factor-related protein-3 (CTRP3), a newly identified adipokine, has been suggested to play important roles in inflammation and metabolism, but the effect of CTRP3 on vascular calcification is unknown. The current study provides compelling evidence that CTRP3 promotes phosphate-induced vascular calcification in vivo, ex vivo, and in vitro. We also demonstrate that CTRP3 promotes vascular calcification by accelerating phosphate-induced osteogenic transition of vascular smooth muscle cells through a reactive oxygen species-extracellular signal-regulated kinase 1/2-runt-related transcription factor 2 signaling pathway. Our findings provide new insights into the important roles of CTRP3 in cardiovascular system and characterize a novel mechanism of adipokine-modulated vascular calcification.
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